Quick Answer
Coherus Oncology, Inc. reported R&D Expense of $108.89 million for fiscal year 2025.
Coherus Oncology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $108.89M | +18.6% |
| 2024 | $91.83M | -16.1% |
| 2023 | $109.44M | -45.1% |
| 2022 | $199.36M | -45.1% |
| 2021 | $363.11M | +154.3% |
| 2020 | $142.76M | +51.6% |
| 2019 | $94.19M | -14.6% |
| 2018 | $110.24M | -32.1% |
| 2017 | $162.39M | -36.2% |
| 2016 | $254.44M | +19.4% |
| 2015 | $213.06M | +172.4% |
| 2014 | $78.22M | +150.1% |
| 2013 | $31.28M | -10.3% |
| 2012 | $34.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.25M | +23.6% | +3.6% |
| June 30, 2025 | $26.31M | +27.7% | +8.0% |
| March 31, 2025 | $24.36M | -14.3% | +10.4% |
| September 30, 2024 | $22.05M | -14.0% | +7.1% |
| June 30, 2024 | $20.60M | -11.5% | -27.5% |
| March 31, 2024 | $28.42M | -16.8% | +10.8% |
| September 30, 2023 | $25.65M | -44.0% | +10.2% |
| June 30, 2023 | $23.27M | -44.1% | -31.9% |
- Coherus Oncology, Inc. showed an increase of +18.6% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Coherus Oncology, Inc.’s r&d expense has grown by 212.1% (from $34.89 million to $108.89 million).
- The most recent figure is from Coherus Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: